Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.

In the September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives , hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (A...

In this episode of Diabetes Dialogue, which was filmed days after the conclusion of ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the conference, their favorite sessions, and how ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

In this edition of Diabetes Dialogue, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management. During her time at the meeting, Clements was the primary presenter for a trio of sessions focus...

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O’Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

In this ADCES 22 special edition episode of Diabetes Dialogue, our hosts are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff pscyhologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward. More information on these sites can be found...

For the July 2022 episode of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

In this edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives our hosts discuss the experiences of their prescribing tirzepatide (Mounjaro) to patients and what types of issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients. 

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Dr. Jasmine Gonzalvo, director of the Center for Health Equity and Innovation at the Purdue University College of Pharmacy, joins hosts Drs. Diana Isaacs and Natalie Bellini to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents...

In our second special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, hosts Drs. Diana Isaacs and Natalie Bellini are joined by Gary Scheiner, MS, CDE. Clinical director of Integrated Diabetes Services, author of multiple books, and former Diabetes Educator of the Year, Scheiner joins Diabetes Dialogue to provide a deep dive into the lar...

In the first of 4 special edition ADA 2022 episodes, hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics's Insulin-Only Bionic Pancreas.

In this episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into what the tirzepatide (Mounjaro) approval, including discussions around the mechanism of action for the first-in-class agent, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hos...

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, provide insight into their favorite sessions from the conference and clinical pearls they took away from their experience, including latest updates in the world of diabetes smart pho...

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of semaglutide 2.0 mg (Ozempic)'s approval, the use of novel glycemic control metrics, and a preview of ATTD 2022.

The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent regulatory news surrounding CGM devices in the US and Europe.  

Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version. 

This episode of the Endocrine Outlook podcast features Thomas Wadden, PhD, a professor of psychology at Perelman School of Medicine at the University of Penn. Wadden is also a principal investigator in the STEP Program, which is a series of clinical trials funded by Novo Nordisk examining subcutaneous semaglutide for inducing weight loss in patients who are obese or overweight.  During this episod...

This episode of the Endocrine Outlook features a conversation with Juan Frias, MD, medical director of the National Research Institute. Frias is also the principal investigator of the SURPASS-2 trial which examined Eli Lilly’s Dual GLP1/GIP agonist tirzepatide against 1mg semaglutide for glucose control and weight loss in patients with diabetes. 

In this episode, Endocrinology Network senior editor Patrick Campbell speaks with Dr. Ariana Chao, of Penn Nursing, about dietary interventions and nutrition. Chao is the lead author of a recent study examining these topics published in the  Journal of Clinical Investigation.

This episode of the Endocrine Outlook features a  recent interview with Dr. Jeffrey Curtis, of the University of Alabama at Birmingham. A rheumatologist and leading expert in osteoporosis research, Curtis and I have a lengthy discussion around osteoporosis and challenges in treating the disease, the impact of the COVID-19 pandemic, and one of the most unrecognized problems in rheumatology: the und...

Dr. Georgiana Dobri, a neuroendocrinologist with Weill Cornell Medicine, discusses the approval of osilodrostat and management of Cushing's disease in 2020.

This episode of the Endocrine Outlook features a conversation with Terri Lipman, PhD, CRNP, of the University of Pennsylvania. In the interview, Lipman discusses and offers perspective on a recent study she led examining disparities in insulin pump use among children with type 1 diabetes.

Raymond Douglas, MD, PhD, discusses trends in therapies and the current state of thyroid eye disease treatments in 2020.